A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

This first-in-human trial is testing a new drug called BMS-986506 in people with advanced clear cell renal cell carcinoma (kidney cancer) that has progressed after prior treatment, to evaluate its safety and how the body responds to it. **You may be eligible if...** - You are 18 or older with a confirmed diagnosis of locally advanced or metastatic clear cell renal cell carcinoma (kidney cancer) - For Part 1 (dose escalation): you have had at least two prior treatments, including both immunotherapy and targeted therapy - For Part 2: you have had at least one prior treatment that included both a PD-1/L1 immune checkpoint inhibitor and a VEGF-targeted therapy (either together or sequentially) - Your general health score (ECOG) is 0 or 1 (fully active or slightly restricted) - You can swallow oral medication whole **You may NOT be eligible if...** - You cannot swallow pills whole (no crushing, breaking, or chewing) - For Part 2A: you have had more than 3 prior systemic treatment regimens - You have other conditions that would make this drug unsafe Talk to your doctor to see if this trial is right for you.